206 related articles for article (PubMed ID: 34756470)
1. Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis.
Goldberg RM; Kim SR; Fazelzad R; Li X; Brown TJ; May T
Gynecol Oncol; 2022 Jan; 164(1):212-220. PubMed ID: 34756470
[TBL] [Abstract][Full Text] [Related]
2. Surgical cytoreduction for recurrent epithelial ovarian cancer.
Al Rawahi T; Lopes AD; Bristow RE; Bryant A; Elattar A; Chattopadhyay S; Galaal K
Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD008765. PubMed ID: 23450588
[TBL] [Abstract][Full Text] [Related]
3. The survival outcome and complication of secondary cytoreductive surgery plus chemotherapy in recurrent ovarian cancer: a systematic review and meta-analysis.
Ding T; Tang D; Xi M
J Ovarian Res; 2021 Jul; 14(1):93. PubMed ID: 34256813
[TBL] [Abstract][Full Text] [Related]
4. The Value of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer and Application of a Prognostic Score.
da Costa AA; Valadares CV; Mantoan H; Saito A; Salvadori MM; Guimarães AP; Sanches SM; Achatz MI; Baiocchi G
Int J Gynecol Cancer; 2016 Mar; 26(3):449-55. PubMed ID: 26825830
[TBL] [Abstract][Full Text] [Related]
5. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.
Cobb LP; Sun CC; Iyer R; Nick AM; Fleming ND; Westin SN; Sood AK; Wong KK; Silva EG; Gershenson DM
Gynecol Oncol; 2020 Sep; 158(3):653-658. PubMed ID: 32709538
[TBL] [Abstract][Full Text] [Related]
6. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
Fader AN; Bergstrom J; Jernigan A; Tanner EJ; Roche KL; Stone RL; Levinson KL; Ricci S; Wethingon S; Wang TL; Shih IM; Yang B; Zhang G; Armstrong DK; Gaillard S; Michener C; DeBernardo R; Rose PG
Gynecol Oncol; 2017 Oct; 147(1):85-91. PubMed ID: 28768570
[TBL] [Abstract][Full Text] [Related]
7. Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes.
Scott SA; Llaurado Fernandez M; Kim H; Elit L; Nourmoussavi M; Glaze S; Roberts L; Offman SL; Rahimi K; Lytwyn A; Sur M; Gilks CB; Matheson K; Köbel M; Dawson A; Tinker AV; Kwon JS; Hoskins P; Santos JL; Cheung A; Provencher D; Carey MS;
Gynecol Oncol; 2020 Apr; 157(1):36-45. PubMed ID: 32001076
[TBL] [Abstract][Full Text] [Related]
8. The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer.
Crane EK; Sun CC; Ramirez PT; Schmeler KM; Malpica A; Gershenson DM
Gynecol Oncol; 2015 Jan; 136(1):25-9. PubMed ID: 25448453
[TBL] [Abstract][Full Text] [Related]
9. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?
Kumar S; Srinivasan A; Phillips A; Madhupriya R; Pascoe J; Nevin J; Elattar A; Balega J; Cummins C; Sundar S; Kehoe ST; Singh K
J Obstet Gynaecol; 2020 Aug; 40(6):849-855. PubMed ID: 31933417
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of secondary cytoreductive surgery for recurrent ovarian, tubal, or peritoneal cancer in Tian-model low-risk patients.
So M; Miyamoto T; Murakami R; Abiko K; Hamanishi J; Baba T; Mandai M
J Gynecol Oncol; 2019 Nov; 30(6):e100. PubMed ID: 31576692
[TBL] [Abstract][Full Text] [Related]
11. Prognostic role of pathologic response and cytoreductive status at interval debulking surgery after neoadjuvant chemotherapy for advanced epithelial ovarian cancer.
Liang MI; Prendergast EN; Staples JN; Holschneider CH; Cohen JG; Cass I
J Surg Oncol; 2019 Sep; 120(4):779-785. PubMed ID: 31283034
[TBL] [Abstract][Full Text] [Related]
12. Tertiary Cytoreduction for Recurrent Epithelial Ovarian Cancer: a Multicenter Study in Turkey.
Arvas M; Salihoglu Y; Sal V; Gungor T; Sozen H; Kahramanoglu I; Topuz S; Demirkiran F; Iyibozkurt C; Bese T; Ozgu BS; Vatansever D; Tokgozoglu N; Berkman S; Turan H; Bengisu E; Sofiyeva N; Demiral I; Meydanli M
Asian Pac J Cancer Prev; 2016; 17(4):1909-15. PubMed ID: 27221875
[TBL] [Abstract][Full Text] [Related]
13. Predictors of favorable survival after secondary cytoreductive surgery for recurrent endometrial cancer.
Shikama A; Minaguchi T; Takao W; Hosokawa Y; Nishida K; Tasaka N; Akiyama A; Sakurai M; Ochi H; Satoh T
Int J Clin Oncol; 2019 Oct; 24(10):1256-1263. PubMed ID: 31098693
[TBL] [Abstract][Full Text] [Related]
14. BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study.
Marchetti C; De Leo R; Musella A; D'Indinosante M; Capoluongo E; Minucci A; Benedetti Panici P; Scambia G; Fagotti A
Ann Surg Oncol; 2018 Nov; 25(12):3701-3708. PubMed ID: 30128899
[TBL] [Abstract][Full Text] [Related]
15. Stage, treatment and survival of low-grade serous ovarian carcinoma in the Netherlands: A nationwide study.
De Decker K; Wenzel HHB; Bart J; van der Aa MA; Kruitwagen RFPM; Nijman HW; Kruse AJ
Acta Obstet Gynecol Scand; 2023 Mar; 102(3):246-256. PubMed ID: 36734363
[TBL] [Abstract][Full Text] [Related]
16. Maximal cytoreduction is related to improved disease-free survival in low-grade ovarian serous carcinoma.
Kimyon Comert G; Turkmen O; Mesci CG; Karalok A; Sever O; Sinaci S; Boran N; Basaran D; Turan T
Tumori; 2019 Jun; 105(3):259-264. PubMed ID: 30915911
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of prognosis and associated factors in multiple recurrent epithelial ovarian cancer with three times or more cytoreductive surgeries].
Zou RY; Yuan L; Chen M; Yao LQ
Zhonghua Fu Chan Ke Za Zhi; 2023 Mar; 58(3):198-206. PubMed ID: 36935197
[No Abstract] [Full Text] [Related]
18. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma.
Shvartsman HS; Sun CC; Bodurka DC; Mahajan V; Crispens M; Lu KH; Deavers MT; Malpica A; Silva EG; Gershenson DM
Gynecol Oncol; 2007 Jun; 105(3):625-9. PubMed ID: 17320156
[TBL] [Abstract][Full Text] [Related]
19. The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer.
Bogani G; Leone Roberti Maggiore U; Paolini B; Diito A; Martinelli F; Lorusso D; Raspagliesi F
J Gynecol Oncol; 2019 Jan; 30(1):e4. PubMed ID: 30479088
[TBL] [Abstract][Full Text] [Related]
20. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
